IMI

Eliciting Patient Preferences on Benefits/Risks of Medicines


PREFER is a 5-year project, partly funded by IMI. It aims to investigate methodologies to elicit informed patient preferences regarding the benefit/risk of drugs, from drug development through the entire life cycle, to inform the decision-making process by regulators and HTA bodies.

MindBytes’ contribution to this project is to use our expertise in Serious Gaming to develop an evidence-based Serious Game as a methodology for patient preference elicitation and health utility assessment. The game should allow us to:

  • Inform patients about the true trade-offs involved with the benefits-risks associated to medicines, both short term and long term
  • Assess which trade-offs patients make (patient preferences)

The Serious Game will incorporate concepts like Discrete Choice Experiments, BEST/WORST scaling and conjoint analysis. It will capture patient’s cognitive and behaviorial profiles to allow for stratification in patient sub-groups. It will align with NICE & Health Economic standards

Integrate with CE models, Outcome data analysis

Partners

  • Uppsala University
  • Newcastle University
  • Erasmus UMC
  • UMC Utrecht
  • KU Leuven
  • European Institute Oncology
  • Muscular Dystrophy UK
  • Novartis
  • Roche
  • Sanofi
  • Takeda
  • Pfizer
  • Various other